Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068860 · ClinicalTrials.gov registry record · Phase 2
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
A Phase 2 study of Type 2 Diabetes Mellitus and Impaired Glucose Tolerance, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
- 20
- Study locations
NCT01068860 is a Phase 2 study of Type 2 Diabetes Mellitus and Impaired Glucose Tolerance that has completed, run by Novartis. The registered enrollment target is 246 participants, below the 2,746-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01068860, a Phase 2 study of Type 2 Diabetes Mellitus and Impaired Glucose Tolerance, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.
Conditions Studied
Interventions
- DRUG Canakinumab 150 mg
- DRUG Placebo to Canakinumab
Study Locations (20)
California
- National Research Institute - Los Angeles
- Crest Clinical Trials - Santa Ana
- Encompass Clinical Research - Spring Valley
Victoria
- Barwon Health - Geelong Hospital - Geelong
- Austin Health - Heidelberg Repatriation Hospital - Heidelberg Heights
- Melbourne Health - Royal Melbourne Hospital - Melbourne
Ontario
- Lifestyle Metabolism Centre (Etobicoke) - Etobicoke
- LMC Endocrinology Centres (Markham) Ltd - Markham
- LMC Endocrinology Centres (Thornhill) Ltd - Thornhill
Nebraska
- University of Nebraska Medical Center - Omaha
- VA Medical Center - Omaha
Texas
- Dallas Diabetes and Endocrine Center - Dallas
- Texas Center for Drug Development P.A. - Houston
Quebec
- Centre de recherche clinique de Laval - Laval
- Hôpital Maisonneuve-Rosemont - Montreal
Kentucky
- Commonwealth Biomedical Research LLC - Madisonville
North Dakota
- Lillestol Research LLC - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068860
The ClinicalTrials.gov registry entry for NCT01068860 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,746-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Canakinumab 150 mg is the first listed.
NCT01068860 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Victoria, Ontario.
Frequently Asked Questions
What is clinical trial NCT01068860 about?
NCT01068860 is a clinical study titled "To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies". This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.
What is the current status of trial NCT01068860?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2010-02. Estimated completion is 2010-08.
What conditions does trial NCT01068860 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance.
What interventions are being tested in trial NCT01068860?
The interventions under investigation include: Canakinumab 150 mg (DRUG), Placebo to Canakinumab (DRUG).
Who is sponsoring clinical trial NCT01068860?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01068860 being conducted?
This trial has 20 study locations across California, Kentucky, Nebraska, North Dakota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.